About Jessica Glennie
Jessica Glennie, CNP, is a certified nurse practitioner, specializing in pulmonology, who has worked in outpatient pulmonary medicine at the Cleveland Clinic in Cleveland, Ohio for 8 years. She manages patients in the interstitial lung disease program, including care of patients with idiopathic pulmonary fibrosis, autoimmune related interstitial lung disease, hypersensitivity pneumonitis, occupational lung diseases, and drug-induced interstitial lung disease. She is co-director of the Cleveland Clinic’s ILD multidisciplinary conference.
ILD Digital Learning Center by Jessica Glennie
Podcasts
Podcasts
ILD & PH-ILD at the Rheum–Pulm Crossroads
November 2025
22:52 m
Join host Amanda Mixon, President of RhAPP, for a special episode recorded live at the 6th Annual RhAPP Conference. In this conversation, Amanda is joined by Jessica Glennie, CNP, from the Cleveland Clinic, to explore the complex intersection of rheumatology and pulmonology, focusing on Interstitial Lung Disease (ILD) and Pulmonary Hypertension in ILD (PH-ILD). Together, they unpack how early recognition, multidisciplinary collaboration, and evidence-based management can improve outcomes for patients with connective tissue disease–related pulmonary complications. Tune in for expert insights, practical diagnostic tips, and highlights from one of the most engaging sessions of the RhAPP National Conference.
Rheumatology in the Lungs
July 2025
24:47 m
How can Advanced Practice Providers (APPs) in rheumatology and pulmonology collaborate more effectively to manage interstitial lung disease (ILD) and connective tissue diseases (CTDs)? In this engaging episode of the APAPP Broadcast, recorded live at the Second Annual National APAPP Conference in Nashville, experts Jessica Glennie, PA-C (Cleveland Clinic), Amanda Mixon, PA-C (Colorado), and Cori Fratelli, NP (National Jewish Health) explore clinical overlaps between autoimmune rheumatic diseases and lung involvement, such as ILD in rheumatoid arthritis, systemic sclerosis (scleroderma), Sjögren’s syndrome, and myositis. The panel shares clinical pearls on: -How to recognize signs of CTDs in pulmonary patients -The importance of labs and imaging in early diagnosis -What rheumatology APPs should ask about pulmonary symptoms -The power of cross-specialty collaboration -Real-world case insights, including navigating bird-related hypersensitivity pneumonitis
Practical Considerations for Screening for PH in ILD Clinics
July 2025
17:17 m
In this insightful Podcast, expert advanced practice providers, Corinne Young & Jessica Glennie share practical strategies for identifying and screening for pulmonary hypertension (PH) in patients with interstitial lung disease (ILD). They discuss how to recognize subtle red flags—such as declining DLCO, changes in walk test performance, and discrepancies in pulmonary function test results—that may indicate the presence of PH. The conversation also covers when to order echocardiograms, when to refer for right heart catheterization, and how to distinguish ILD progression from the development of PH. With a focus on multidisciplinary collaboration and real-world clinical workflows, this episode offers valuable, actionable guidance for APPs, pulmonologists, and care teams managing ILD populations.
Advancing ILD & PH-ILD Care
July 2025
21:35 m
Join Jessica Glennie, APRN, and Lori Reed, FNP, from the 2025 APAPP National Conference as they discuss key insights in diagnosing and managing interstitial lung disease (ILD) and pulmonary hypertension (PH). From interpreting PFTs and recognizing red flags to exploring current and emerging therapies like inhaled treprostinil and neuredomast, this episode offers practical strategies for improving patient care. Tune in for expert tips and updates every pulmonary provider should know.
ILD 101, ILD 102, ILD Peds
July 2025
20:57 m
Join Jessica Glennie, APRN, Naomi Miyazawa, PA-C, and Cori Fratelli, FNP, from the 2025 APAPP National Conference as they explore pediatric and adult interstitial lung disease (ILD). This episode covers diagnosis, disease progression, anti-inflammatory and anti-fibrotic therapies, and the importance of multidisciplinary care. Learn about pediatric ILD (CHILD), autoimmune-related ILD, and new treatment guidelines—all through real-world clinical insights.
FAQ
FAQ
How can clinicians distinguish PH-ILD from progression of interstitial lung disease alone?
February 2026
08:11 m
In this clinical update, Jessica Glennie, CNP, from the Cleveland Clinic Interstitial Lung Disease Group, explains how to differentiate worsening interstitial lung disease (ILD) or progressive pulmonary fibrosis (PPF) from developing or worsening pulmonary hypertension (PH). Because patients often present with overlapping symptoms such as shortness of breath, fatigue, and decreased exercise tolerance, she outlines a practical diagnostic approach using NT-proBNP, spirometry (FVC), DLCO trends, the FVC/DLCO ratio, six-minute walk testing, high-resolution CT imaging, echocardiogram findings (including RVSP and TAPSE), and when to consider right heart catheterization. This concise review helps clinicians determine whether pulmonary hypertension or ILD progression is driving a patient’s decline and supports more informed clinical decision-making.
Webcast
Webcast
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
37:44 m
This webcast provides a practical, case-based look at identifying and managing interstitial lung disease (ILD) in patients with autoimmune conditions, with a focus on rheumatoid arthritis and systemic sclerosis. Through real-world scenarios, expert clinicians, Betsy Kirchner, DNP and Jessica Glennie, MSN, APRN highlight key risk factors, early warning signs like exertional dyspnea and inspiratory crackles, and the importance of timely screening with pulmonary function tests and high-resolution CT imaging. The discussion emphasizes collaborative care between rheumatology and pulmonology, outlining treatment strategies that balance immunosuppression and antifibrotic therapy to slow disease progression. Attendees will gain actionable insights on early detection, multidisciplinary management, and optimizing patient outcomes in ILD.
Industry Resources
WANT EXPERT PERSPECTIVES ON INTERSTITIAL LUNG DISEASE?